Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion

Retina

Volumn 29, Issue 4, 2009, Pages 511-515

  Russo, Vincenzo ^a   Barone, Antonio ^a,b   Conte, Emanuele ^a   Prascina, Francesco ^a   Stella, Andrea ^a   Noci, Nicola Delle ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Ospedali Riuniti di Foggia   (Italy)

Author keywords

Branch retinal vein occlusion; Cystoid macular edema; Intravitreal bevacizumab

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARGON LASER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; EYE TOXICITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; LASER COAGULATION; LENS DISEASE; MALE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; COMPARATIVE STUDY; DRUG ANTAGONISM; INJECTION; PATHOLOGY; PATHOPHYSIOLOGY; RETINA MACULA LUTEA; SPECTACLES; VITREOUS BODY;

ANTIBODIES, MONOCLONAL; EYEGLASSES; FEMALE; HUMANS; INJECTIONS; LASER COAGULATION; MACULA LUTEA; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 66149138872     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318195ca65     Document Type: Article

References (34)

1. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
2. Bearelly S, Fekrat S. Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin 2004;44:85-102.
3. Parodi MB. Medical treatment of retinal vein occlusions. Semin Ophthalmol 2004;19:43-48.
4. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-854.
5. Chen SD, Sundaram V, Lochhead P, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-883.
6. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolon acetonide for treatment of persistent macular edema in branch retinal vein occlusion. Eye 2006;20:13-17.
7. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema Am J Ophthalmol 2005;140:695-702.
8. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-855.
9. Miller SD. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1985;99:218-219.
10. Gaudric A, Giorgi F, Sterkers M, Chaine G, Coscas G. Photocoagulation au laser à argon dans l'oedème maculaire cystoïde des occlusions veineuses rétiniennes. A propos de 68 cas. J Fr Ophtalmol 1988;11:319-326.
11. Glacet-Bernard A, Nouri Mahdavi K, Coscas G, Zourdani A, Fardeau C. Macular grid photocoagulation in persistent macular edema due to central vein occlusion. Eur J Ophthalmol 1994;4: 166-174.
12. Gutman FA, Zegarra H, Nothnagel A. Laser treatment of macular edema secondary to central vein occlusion. Int Ophthalmol 1987;10:100-101.
13. Klein ML, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 1989;107:1297-1302.
14. Soubrane G. Macular edema in retinal vein occlusion: up-date from the central retinal vein occlusion study. Doc Ophthalmol 1999;97:279-281.
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
16. Jaissle GB, Ziemssen F, Petermeier K, et al. Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2006;103:471-475.
17. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
18. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
19. Esrick E, Subramanian ML, Heir JS, et al. Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 2005;139:653-657.
20. Hayreh SS, Rubenstein L, Podhajsky P. Argon laser scatter photocoagulation in treatment of branch retinal vein occlusion. A prospective trial. Ophthalmologica 1993;206:1-14.
21. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Research Group report number 2. Ophthalmology 1987;94:761-774.
22. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. Retina 1985;5:65-72.
23. Lee C, Olk J. Modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1991;98:1594-1602.
24. Degenring RF, Hugger P, Sauder G, Jonas JB. Grid laser photocoagulation in diffuse diabetic macular edema. Klin Monatsbl Augenheilkd 2004;221:48-51.
25. Hockley DJ, Tripathi RC, Ashton N. Experimental branch vein occlusion in rhesus monkeys, III. Br J Ophthalmol 1979;63:393- 411.
26. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997;12:99-109.
27. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843-845.
28. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996;37:1334 -1340.
29. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
30. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412- 416.
31. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
32. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695; e1-e15.
33. Schultz A, Lavie L, Hochberg I, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999;100:547-552.
34. Lin TH, Yen HW, Voon WC, et al. Vascular endothelial growth factor in coronary sinus: evidence for its association with coronary collaterals. Scand Cardiovasc J 2005;39:353-357.